Kidney Transplant Rejection – Pipeline Review, H2 2019

Global Markets Direct’s, ‘Kidney Transplant Rejection – Pipeline Review, H2 2019’, provides an overview of the Kidney Transplant Rejection pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Kidney Transplant Rejection, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Kidney Transplant Rejection and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Kidney Transplant Rejection

– The report reviews pipeline therapeutics for Kidney Transplant Rejection by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Kidney Transplant Rejection therapeutics and enlists all their major and minor projects

– The report assesses Kidney Transplant Rejection therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Kidney Transplant Rejection

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Kidney Transplant Rejection

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Kidney Transplant Rejection pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Alphamab Oncology

Amgen Inc

Amyndas Pharmaceuticals LLC

Astellas Pharma Inc

Bristol-Myers Squibb Co

Enceladus Pharmaceuticals BV

Gilead Sciences Inc

Hansa Biopharma AB

Helocyte Biosciences Inc

Hillhurst Biopharmaceuticals Inc

Idogen AB

ITB-Med AB

JN Biosciences LLC

Kiniksa Pharmaceuticals Corp

Kyowa Kirin Co Ltd

Mabtech Ltd

Medeor Therapeutics Inc

MyeloRx LLC

Nekonal Sarl

NextCell Pharma AB

Novartis AG

OSE Immunotherapeutics

Pharmapraxis

Pharmicell Co Ltd

Rigel Pharmaceuticals Inc

Sangamo Therapeutics Inc

St George Street Capital Ltd

Talaris Therapeutics Inc

TolerogenixX GmbH

TRACT Therapeutics Inc

Veloxis Pharmaceuticals AS

Viela Bio Inc

Table of Contents

Table of Contents

Table of Contents 2

Introduction 5

Kidney Transplant Rejection - Overview 6

Kidney Transplant Rejection - Therapeutics Development 7

Kidney Transplant Rejection - Therapeutics Assessment 16

Kidney Transplant Rejection - Companies Involved in Therapeutics Development 26

Kidney Transplant Rejection - Drug Profiles 37

Kidney Transplant Rejection - Dormant Projects 153

Kidney Transplant Rejection - Discontinued Products 156

Kidney Transplant Rejection - Product Development Milestones 157

Appendix 169

List of Tables

List of Tables

Number of Products under Development for Kidney Transplant Rejection, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Products under Development by Universities/Institutes, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Kidney Transplant Rejection – Pipeline by Alphamab Oncology, H2 2019

Kidney Transplant Rejection – Pipeline by Amgen Inc, H2 2019

Kidney Transplant Rejection – Pipeline by Amyndas Pharmaceuticals LLC, H2 2019

Kidney Transplant Rejection – Pipeline by Astellas Pharma Inc, H2 2019

Kidney Transplant Rejection – Pipeline by Bristol-Myers Squibb Co, H2 2019

Kidney Transplant Rejection – Pipeline by Enceladus Pharmaceuticals BV, H2 2019

Kidney Transplant Rejection – Pipeline by Gilead Sciences Inc, H2 2019

Kidney Transplant Rejection – Pipeline by Hansa Biopharma AB, H2 2019

Kidney Transplant Rejection – Pipeline by Helocyte Biosciences Inc, H2 2019

Kidney Transplant Rejection – Pipeline by Hillhurst Biopharmaceuticals Inc, H2 2019

Kidney Transplant Rejection – Pipeline by Idogen AB, H2 2019

Kidney Transplant Rejection – Pipeline by ITB-Med AB, H2 2019

Kidney Transplant Rejection – Pipeline by JN Biosciences LLC, H2 2019

Kidney Transplant Rejection – Pipeline by Kiniksa Pharmaceuticals Corp, H2 2019

Kidney Transplant Rejection – Pipeline by Kyowa Kirin Co Ltd, H2 2019

Kidney Transplant Rejection – Pipeline by Mabtech Ltd, H2 2019

Kidney Transplant Rejection – Pipeline by Medeor Therapeutics Inc, H2 2019

Kidney Transplant Rejection – Pipeline by MyeloRx LLC, H2 2019

Kidney Transplant Rejection – Pipeline by Nekonal Sarl, H2 2019

Kidney Transplant Rejection – Pipeline by NextCell Pharma AB, H2 2019

Kidney Transplant Rejection – Pipeline by Novartis AG, H2 2019

Kidney Transplant Rejection – Pipeline by OSE Immunotherapeutics, H2 2019

Kidney Transplant Rejection – Pipeline by Pharmapraxis, H2 2019

Kidney Transplant Rejection – Pipeline by Pharmicell Co Ltd, H2 2019

Kidney Transplant Rejection – Pipeline by Rigel Pharmaceuticals Inc, H2 2019

Kidney Transplant Rejection – Pipeline by Sangamo Therapeutics Inc, H2 2019

Kidney Transplant Rejection – Pipeline by St George Street Capital Ltd, H2 2019

Kidney Transplant Rejection – Pipeline by Talaris Therapeutics Inc, H2 2019

Kidney Transplant Rejection – Pipeline by TolerogenixX GmbH, H2 2019

Kidney Transplant Rejection – Pipeline by TRACT Therapeutics Inc, H2 2019

Kidney Transplant Rejection – Pipeline by Veloxis Pharmaceuticals AS, H2 2019

Kidney Transplant Rejection – Pipeline by Viela Bio Inc, H2 2019

Kidney Transplant Rejection – Dormant Projects, H2 2019

Kidney Transplant Rejection – Dormant Projects, H2 2019 (Contd..1), H2 2019

Kidney Transplant Rejection – Dormant Projects, H2 2019 (Contd..2), H2 2019

Kidney Transplant Rejection – Discontinued Products, H2 2019

List of Figures

List of Figures

Number of Products under Development for Kidney Transplant Rejection, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Number of Products by Top 10 Targets, H2 2019

Number of Products by Stage and Top 10 Targets, H2 2019

Number of Products by Top 10 Mechanism of Actions, H2 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Top 10 Molecule Types, H2 2019

Number of Products by Stage and Top 10 Molecule Types, H2 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports